HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Psychiatry1 paper

Diffuse atrophy of cerebrum

Last edited: 4/10/2026

Overview

Diffuse cerebral atrophy refers to a generalized reduction in brain volume. While gray matter atrophy is recognized in conditions like schizophrenia, its neurodegenerative nature is debated 1. The brain age gap (BAG), the difference between predicted and chronological brain age, is being investigated as a potential biomarker for early neurodegeneration 1.

Diagnosis

  • Schizophrenia is associated with a significantly higher brain age gap (BAG) compared to healthy controls 1.
  • BAG can significantly discriminate individuals with schizophrenia from healthy controls 1.

    • Management

  • No management strategies for diffuse cerebral atrophy are discussed in the provided abstracts.

    • Special Populations

  • No information on special populations is available in the provided abstracts.

    • Key Recommendations

  • The brain age gap (BAG) may serve as a biomarker for early-stage neurodegeneration 1. (Evidence: Moderate)
  • In schizophrenia, a significantly higher BAG compared to healthy controls has been identified 1. (Evidence: Moderate)
  • The brain age gap (BAG) has the potential to significantly discriminate individuals with schizophrenia from healthy controls 1. (Evidence: Moderate)

    • References

    1 Man W, Ding H, Chai C, An X, Liu F, Qin W et al.. Brain age gap as a potential biomarker for schizophrenia: A multi-site structural MRI study. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2021. link

    Original source

    1. [1]
      Brain age gap as a potential biomarker for schizophrenia: A multi-site structural MRI study. — Man W, Ding H, Chai C, An X, Liu F, Qin W et al. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference (2021)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG